• Are US pharma companies immune to US–Canada trade wars?

  The escalating trade war between the US and Canada could be a disaster for US...
  Read More...

• Regenerative therapy for peripheral artery disease moves forward

  Encouraging Phase II results were released last week for Pluristem’s PLX-PAD, a placenta-based allogeneic stem...
  Read More...

• Shaky foundations: the flaws in animal research reporting

  A new systematic analysis has reiterated concerns over the quality of reporting for preclinical efficacy...
  Read More...

• ViiV ups the ante with positive topline data for its second two-drug HIV combo

  On June 14, ViiV Healthcare announced positive topline results from its Phase III GEMINI 1...
  Read More...

• Thailand: from medical tourism to contract manufacturing

  Thailand hopes to use its strength in medical tourism to grow its pharmaceutical sector, claimed...
  Read More...

• Pharma underutilises avenues to attract and retain trial patients

  Pharma companies can better attract patients to clinical trials through working with patient advocacy groups...
  Read More...

• EMA approval for Trazimera: another win for trastuzumab biosimilars

  On May 31, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use...
  Read More...

• EHA 2018: competition is heating up in DLBCL for anti-CD19 CAR-T cell therapies

  Numerous highly attended clinical data and educational sessions were hosted about CAR-T cell therapy at...
  Read More...

• EAN Congress 2018: refractory migraine and the problem with prevention

  Migraine is the most prevalent brain disorder in the world, and yet, until earlier this...
  Read More...

• EAN Congress 2018: brain disorders – where is the value?

  Brain disorders (mental and neurological disorders) represent 35% of Europe’s total disease burden, and a...
  Read More...